Several investor-rights law firms announce securities class actions involving Erasca, Inc. (NASDAQ: ERAS). The filings allege investor harm tied to the company’s disclosures and related events. One announcement states that a class action is filed on behalf of investors who purchased or acquired Erasca securities between January 14, 2025 and April 26, 2026. Another source says a separate class action has been filed against Erasca and certain officers, seeking damages for investors.
A third source connects the dispute to a market reaction following allegations by Revolution Medicines (RevMed) accusing Erasca of patent infringement. That outlet reports that Erasca’s shares fell by about 48% (a drop described as $9.25) and attributes the decline to the patent-infringement accusation involving Erasca’s pan-RAS molecular glue program targeting solid tumors.
Across the announcements, the lawsuits are presented as pending litigation and centered on claimed impacts to investors’ positions. Specific allegations and legal theories are described in outline terms, while financial and market context is provided through reported share-price movement and referenced patent claims.
